Mark Clemons


Ontology type: schema:Person     


Person Info

NAME

Mark

SURNAME

Clemons

Publications in SciGraph latest 50 shown

  • 2019-04 Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC) in SUPPORTIVE CARE IN CANCER
  • 2018-10 Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review in BREAST CANCER RESEARCH AND TREATMENT
  • 2018-09 Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study in SUPPORTIVE CARE IN CANCER
  • 2018-07 Filgrastim use in patients receiving chemotherapy for early-stage breast cancer—a survey of physicians and patients in SUPPORTIVE CARE IN CANCER
  • 2018-04 A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2018-03 Guidelines versus individualized care for the management of CINV in SUPPORTIVE CARE IN CANCER
  • 2018-03 Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—CME information in SUPPORTIVE CARE IN CANCER
  • 2017-12 Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy in NPJ BREAST CANCER
  • 2017-08 A cost-utility analysis of risk model-guided versus physician’s choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach in SUPPORTIVE CARE IN CANCER
  • 2017-06 Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients in SUPPORTIVE CARE IN CANCER
  • 2017-01 Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel–cyclophosphamide chemotherapy for breast cancer: a systematic review in BREAST CANCER RESEARCH AND TREATMENT
  • 2016-11 Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2016-09 Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review in CANCER AND METASTASIS REVIEWS
  • 2016-08 Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review in SUPPORTIVE CARE IN CANCER
  • 2016-04 Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors in SUPPORTIVE CARE IN CANCER
  • 2016-04 Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review in SUPPORTIVE CARE IN CANCER
  • 2016-03 The effect of melatonin on sleep and quality of life in patients with advanced breast cancer in SUPPORTIVE CARE IN CANCER
  • 2016-01 A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2016 Oncodynamic Changes in Skeleton in ONCODYNAMICS: EFFECTS OF CANCER CELLS ON THE BODY
  • 2016-01 Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting in BREAST CANCER RESEARCH AND TREATMENT
  • 2015-12 Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses in SYSTEMATIC REVIEWS
  • 2015-12 A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22 in SPRINGERPLUS
  • 2015-11 Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy—a survey of health care providers and patients in SUPPORTIVE CARE IN CANCER
  • 2015-11 Defining optimal control of chemotherapy-induced nausea and vomiting—based on patients’ experience in SUPPORTIVE CARE IN CANCER
  • 2015-07 Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials in BREAST CANCER RESEARCH AND TREATMENT
  • 2015-04 Erratum to: Platinum-based chemotherapy in triple-negative advanced breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2014-12 Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer in SPRINGERPLUS
  • 2014-12 Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases in SPRINGERPLUS
  • 2014-08 Platinum-based chemotherapy in triple-negative advanced breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2014-08 Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival in BREAST CANCER RESEARCH AND TREATMENT
  • 2014-07 Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study in BREAST CANCER RESEARCH AND TREATMENT
  • 2014-04 Risk prediction models for chemotherapy-induced nausea and vomiting: almost ready for prime time? in SUPPORTIVE CARE IN CANCER
  • 2014-04 A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events in BREAST CANCER RESEARCH AND TREATMENT
  • 2014 Assessment of Therapeutic Response Through Clinical Assessment Measures in BONE METASTASES
  • 2013-11 Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials in BREAST CANCER RESEARCH AND TREATMENT
  • 2013-11 Preference weights for chemotherapy side effects from the perspective of women with breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2013-10 Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer in BREAST CANCER RESEARCH
  • 2013-08 The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study in BREAST CANCER RESEARCH AND TREATMENT
  • 2013-06 Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-12 Content validation of the EORTC QLQ-BN20+2 with patients and health care professionals to assess quality of life in brain metastases in JOURNAL OF RADIATION ONCOLOGY
  • 2012-12 ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone in BREAST CANCER RESEARCH
  • 2012-07 Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated? in BREAST CANCER RESEARCH AND TREATMENT
  • 2011-11 Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists in SUPPORTIVE CARE IN CANCER
  • 2011-10 Acquisition of metastatic tissue from patients with bone metastases from breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2011-03 Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials in SUPPORTIVE CARE IN CANCER
  • 2010-11 Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy in BREAST CANCER RESEARCH AND TREATMENT
  • 2010-04 Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2010-02 Chemotherapy: Dose-dense treatment for triple-negative breast cancer in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2010-02 Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting in SUPPORTIVE CARE IN CANCER
  • 2009-12 Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples in CLINICAL & EXPERIMENTAL METASTASIS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.28046.38", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5379.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415354.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414246.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.21925.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412687.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.17063.33", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417181.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419945.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413104.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.25073.33", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412745.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413292.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416193.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415720.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.420748.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.214458.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413629.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414980.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.239826.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.231844.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412917.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415224.4", 
            "type": "Organization"
          }
        ], 
        "familyName": "Clemons", 
        "givenName": "Mark", 
        "id": "sg:person.01216107435.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216107435.90"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:47", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_519.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01216107435.90'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01216107435.90'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01216107435.90'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01216107435.90'


     

    This table displays all metadata directly associated to this object as RDF triples.

    60 TRIPLES      10 PREDICATES      33 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01216107435.90 schema:affiliation Nddf47178b15243c68f4057ee7bda5a31
    2 https://www.grid.ac/institutes/grid.17063.33
    3 https://www.grid.ac/institutes/grid.214458.e
    4 https://www.grid.ac/institutes/grid.21925.3d
    5 https://www.grid.ac/institutes/grid.231844.8
    6 https://www.grid.ac/institutes/grid.239826.4
    7 https://www.grid.ac/institutes/grid.25073.33
    8 https://www.grid.ac/institutes/grid.412687.e
    9 https://www.grid.ac/institutes/grid.412745.1
    10 https://www.grid.ac/institutes/grid.412917.8
    11 https://www.grid.ac/institutes/grid.413104.3
    12 https://www.grid.ac/institutes/grid.413292.f
    13 https://www.grid.ac/institutes/grid.413629.b
    14 https://www.grid.ac/institutes/grid.414246.1
    15 https://www.grid.ac/institutes/grid.414980.0
    16 https://www.grid.ac/institutes/grid.415224.4
    17 https://www.grid.ac/institutes/grid.415354.2
    18 https://www.grid.ac/institutes/grid.415720.5
    19 https://www.grid.ac/institutes/grid.416193.8
    20 https://www.grid.ac/institutes/grid.417181.a
    21 https://www.grid.ac/institutes/grid.419945.4
    22 https://www.grid.ac/institutes/grid.420748.d
    23 https://www.grid.ac/institutes/grid.5379.8
    24 schema:familyName Clemons
    25 schema:givenName Mark
    26 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216107435.90
    27 schema:sdDatePublished 2019-03-07T14:47
    28 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    29 schema:sdPublisher N0e4d10272cc94a3ea6441c3fa87a8f5b
    30 sgo:license sg:explorer/license/
    31 sgo:sdDataset persons
    32 rdf:type schema:Person
    33 N0e4d10272cc94a3ea6441c3fa87a8f5b schema:name Springer Nature - SN SciGraph project
    34 rdf:type schema:Organization
    35 Nddf47178b15243c68f4057ee7bda5a31 schema:affiliation https://www.grid.ac/institutes/grid.28046.38
    36 sgo:isCurrent true
    37 rdf:type schema:OrganizationRole
    38 https://www.grid.ac/institutes/grid.17063.33 schema:Organization
    39 https://www.grid.ac/institutes/grid.214458.e schema:Organization
    40 https://www.grid.ac/institutes/grid.21925.3d schema:Organization
    41 https://www.grid.ac/institutes/grid.231844.8 schema:Organization
    42 https://www.grid.ac/institutes/grid.239826.4 schema:Organization
    43 https://www.grid.ac/institutes/grid.25073.33 schema:Organization
    44 https://www.grid.ac/institutes/grid.28046.38 schema:Organization
    45 https://www.grid.ac/institutes/grid.412687.e schema:Organization
    46 https://www.grid.ac/institutes/grid.412745.1 schema:Organization
    47 https://www.grid.ac/institutes/grid.412917.8 schema:Organization
    48 https://www.grid.ac/institutes/grid.413104.3 schema:Organization
    49 https://www.grid.ac/institutes/grid.413292.f schema:Organization
    50 https://www.grid.ac/institutes/grid.413629.b schema:Organization
    51 https://www.grid.ac/institutes/grid.414246.1 schema:Organization
    52 https://www.grid.ac/institutes/grid.414980.0 schema:Organization
    53 https://www.grid.ac/institutes/grid.415224.4 schema:Organization
    54 https://www.grid.ac/institutes/grid.415354.2 schema:Organization
    55 https://www.grid.ac/institutes/grid.415720.5 schema:Organization
    56 https://www.grid.ac/institutes/grid.416193.8 schema:Organization
    57 https://www.grid.ac/institutes/grid.417181.a schema:Organization
    58 https://www.grid.ac/institutes/grid.419945.4 schema:Organization
    59 https://www.grid.ac/institutes/grid.420748.d schema:Organization
    60 https://www.grid.ac/institutes/grid.5379.8 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...